Effects of equine recombinant interleukin-1alpha and interleukin-1beta on proteoglycan metabolism and prostaglandin E2 synthesis in equine articular cartilage explants.

This research study explores the effects of equine recombinant interleukin-1alpha (rEqIL-1alpha) and recombinant interleukin-1beta (rEqIL-1beta) on cartilage health in horses. The researchers found that these treatments affect the metabolism of cartilage cells and potentially contribute to joint disease in horses.

Experimental Methodology

• The researchers procured near full-thickness articular cartilage explants, roughly 50 milligrams, from the stifle joints of two horses, one aged three years and the other five years. The cartilage pieces were treated with varying concentrations of rEqIL-1alpha or rEqIL-1beta.
• The team created expression constructs containing cDNA sequences to encode EqIL-1alpha and EqIL-1beta. These constructs were then produced on a large scale in prokaryotic cells and the resultant protein was purified for the experiment.

Analysis Technique and Measurements

• Post-treatment, the researchers used a specific dye (1,9-dimethylmethylene blue) to analyze the explant media for glycosaminoglycan (GAG) concentration, a measure of proteoglycan release. They also noted the release of radiolabeled GAG to the explant media.
• The synthesis of proteoglycan was gauged by detecting the extent of radioisotope incorporation into the proteoglycan structures.
• The team also evaluated the prostaglandin E2 (PGE2) concentrations, which is a molecule linked with inflammation, in the explant media using a specific assay method.

Key Findings

• Both rEqIL-1alpha and rEqIL-1beta treatments triggered proteoglycan release at concentrations higher than or equal to 0.1 nanograms/milliliter. It was observed that 38% to 76% of total GAG was released by day 4, increasing to 88%-98% by day 6.
• Simultaneously, proteoglycan synthesis was inhibited by 42% to 64% at interleukin-1 levels greater than or equal to 0.1 nanograms/milliliter, with increased suppression observed on day 2 and day 4.
• There was a marked increase in PGE2 concentrations at interleukin-1 concentrations higher than or equal to 0.1 nanograms/milliliter on day 2 and day 4.

Conclusion

• The study concluded that the rEqIL-1 treatments significantly disrupted equine chondrocyte (cartilage cell) metabolism, thereby suggesting that these treatments may contribute to equine joint disease.
• The results also hinted at the potential use of this experimental model for studying the pathogenesis and treatment strategies of joint disease in horses in a laboratory setting.